Table 2.

Relationship of TP53, CDKN2A, PIK3CA, HRAS mutation with clinical-pathological factors

	TP53		p value	CDKN2A		p value	PIK3CA		p value	HRAS		p value
	Positive (n = 19)	Negative (n = 27)		Positive (n = 11)	Negative (n = 35)		Positive (n = 3)	Negative (n = 43)		Positive (n = 8)	Negative (n = 38)
HPE size (cm)
≥ 4 (n = 10)	8	3	0.032*	3	8	0.526	2	9	0.073	1	10	0.405
< 4 (n = 26)	11	24		8	27		1	34		7	28
Site
Tongue			0.462			0.330			0.261			0.882
Yes	6	7		2	11		0	13		2	11
No	13	20		9	24		3	30		6	27
Buccal mucosa			0.402			0.301			0.499			0.892
Yes	9	15		7	17		1	23		4	20
No	10	12		11	18		2	20		4	18
Lower alveolus			0.484			0.555			0.004*			0.228
Yes	3	3		1	5		2	4		0	6
No	16	24		10	30		1	39		8	32
Upper alveolus			0.413			0.239			1.000			1.000
Yes	1	0		1	0		0	1		0	1
No	18	27		10	35		3	42		8	37
Lower lip			0.339			1.000			1.000			0.002*
Yes	0	2		0	2		0	2		2	0
No	19	25		11	33		3	41		6	38
HPE grade
Moderately differentiated	10	10	0.337	3	17	0.371	2	18	0.686	3	17	0.705
Well differentiated	9	15		7	17		1	23		5	19
Poorly differentiated	0	2		1	1		0	2		0	2
Vascular invasion
Yes	7	6	0.225	2	11	0.330	1	12	1.000	2	11	0.882
No	12	21		9	24		2	31		6	27
Perineural invasion
Yes	9	11	0.442	3	17	0.187	3	17	0.041*	2	18	0.246
No	10	16		8	18		0	26		6	20
Depth invasion
< 5	3	1	0.143	1	3	0.642	0	4	0.571	0	4	0.316
5–10	7	17		7	17		1	23		6	18
> 10	9	9		3	15		2	16		2	16
Lymph node positivity
Yes	6	8	0.570	3	11	0.556	1	13	0.910	3	11	0.633
No	13	19		8	24		2	30		5	27
Extra nodal extension
Yes	2	5	0.457	1	6	0.459	0	7	1.000	1	6	1.000
No	17	22		10	29		3	36		7	32
T status
T2	8	15	0.660	8	15	0.127	0	23	0.036*	5	18	0.057
T3	4	4		0	8		0	8		3	5
T4	7	8		3	12		3	12		0	15
Stage
I	1	0	0.453	0	1	0.282	0	1	0.086	0	1	0.880
II	9	13		8	14		0	22		4	18
III	3	4		0	7		0	7		1	6
IVa	6	7		2	11		3	10		3	10
IVb	0	3		1	2		0	3		0	3

*statistically significant